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Intervirology 2010;53:29-38 30 and the development of HCC increased progressively in a direct relationship with HBV DNA levels at study entry [2, 4] . In particular, HBV DNA levels of 4 log 10 copies/ml or greater were associated with a significant risk for cirrhosis and the development of HCC [2, 4] . The study also showed that patients with increasing levels of HBV DNA over time or with persistently increased levels during follow-up evaluation had the highest risk of HCC. In contrast, lowering of HBV DNA levels from the highest points was linked with a reduction in risk of HCC only when HBV DNA decreased to less than 4 log 10 copies/ml [2] . However, in a recent subanalysis of the REVEAL cohort, a viral titer lower than 4 log 10 copies/ml does not seem to be safe enough to prevent the development of HCC. Iloeje et al. [3] found that individuals with levels of HBV DNA lower than 4 log 10 copies/ml have a 4-fold increased risk for liver-cancer related mortality, compared with uninfected (HBsAg-negative) individuals. In addition, individuals with persistently low levels of HBV DNA ( 6 300 to ! 4 log 10 copies/ml) had an increased risk of developing HCC, compared with patients whose HBV DNA levels were persistently undetectable ( ! 300 copies/ml).
CHB patients whose HBV DNA were persistently suppressed with antiviral agents provided compelling evidence that reduction of HBV DNA levels improves histological and clinical outcomes [16] [17] [18] [19] [20] [21] [22] [23] . In a review of 26 prospective clinical trials, there were strong correlations between the reduction of serum HBV DNA level on treatment and histological improvement [24] . In lamivudineresistant decompensated cirrhotic patients, treatment Undetectable HBV DNA by PCR-based assays  63  72  79  88  51  90  93  Normalization of ALT  38  74  65  74  72  78  76  Histologic improvement  48  63  59  66  64  70  72 Adapted from references [16, [19] [20] [21] [22] [70] [71] [72] . a HBeAg seroconversion. with adefovir improved Child-Pugh scores [25] . In addition, long-term treatment with lamivudine in CHB patients reduces the progression of liver disease, with lower frequency of hepatic decompensation, fewer episodes of spontaneous bacterial peritonitis and esophageal variceal bleeding, and a reduced rate of HCC. These effects were especially dramatic in patients with persistent suppression of viral replication [5] .
HBeAg-negative patients
Therefore, these studies provide evidence that viral replication plays a critical role in the progression of chronic HBV infection and the development of HCC, thus convincingly establishing a rationale for antiviral therapy to suppress HBV DNA completely in a sustained manner.
Nomenclature of Antiviral Resistance
At the 2006 National Institute of Health Workshop on HBV, standardizing the nomenclature of antiviral resistance was proposed ( table 2 ) [10, 26, 27] .
Primary treatment failure (non-response) is defined as the inability of NAs to reduce serum HBV DNA to 6 1 log 10 IU/ml after the first 6 months of treatment. Primary treatment failure may be related to host, viral and drug factors. Polymorphism of host enzymes that are involved in converting prodrugs to their active compound or phosphorylating NAs to their triphosphate may contribute to primary treatment failure [28] . The potency of the antiviral agents might be important. Primary treatment failure was frequently reported in patients taking adefovir but not entecavir or tenofovir, which are 2 very potent antiviral agents. Suboptimal dose of adefovir 10 mg might be associated with primary treatment failure [21] . Monitoring of primary treatment failure is an indication to change antiviral agents because residual viral levels after 6-12 months of therapy increased the risk of antiviral resistance [19, [29] [30] [31] [32] .
Virologic breakthrough or secondary treatment failure is defined as an increase in serum HBV DNA by 6 1 log 10 IU/ml above nadir on 2 or more consecutive occasions at least 1 month apart on treatment after achieving an initial response in compliant patients. This is the first clinical evidence of the development of antiviral resistance [26] . Serum HBV DNA levels initially tended to be low because most antiviral resistant mutants have a low replication fitness compared with wild-type virus. However, with time compensatory mutations, such as rtL80I/ V, rtL180M, rtV173L in lamivudine-resistant patients, develop and restore the replication fitness, so enabling the mutant virus to replicate at near wild-type levels [33] [34] [35] . Eventually, the viral load during continuous treatment returns to and sometimes exceeds pretreatment levels [33, 36] .
Biochemical breakthrough is defined as an elevation in serum ALT level while on treatment after achieving normalization in compliant patients. Biochemical breakthrough usually lags behind virologic breakthrough, and serum ALT levels may remain normal for weeks to years after the development of antiviral resistance [37] [38] [39] . Increase in serum HBV DNA by ≥1 log 10 above nadir on ≥2 occasions 1 month apart, while on treatment, after achieving initial response in a medication-compliant patient.
Viral rebound
Increase in serum HBV DNA to ≥20,000 IU/ml or above pretreatment level after achieving virologic response, during continued treatment.
Biochemical breakthrough
Elevation in serum ALT while on treatment, after achieving normalization in a medicationcompliant patient.
Genetic barrier Threshold probability that the virus will mutate and escape from the selective action of the drug, thereby making the virus resistant to specific drug. Number of amino acid substitutions needed for development of primary antiviral drug resistance.
Genotypic resistance
Detection of viral populations bearing amino acid substitutions in the reverse transcriptase region of the HBV genome that have been shown to confer resistance to antiviral drugs in phenotypic assay, during antiviral therapy. These mutations are usually detected in patients with virologic breakthrough but they can also be present in patients with persistent viremia and no virologic breakthrough.
Phenotypic resistance
Decreased susceptibility of an HBV polymerase to an antiviral treatment in vitro.
Cross resistance Decreased susceptibility to more than 1 antiviral drug conferred by the same amino acid substitution or combination of amino acid substitutions.
Song
Intervirology 2010;53:29-38 32 Genotypic resistance refers to the detection of viral population bearing amino acid substitution in the reverse transcriptase region of the HBV genome that has been shown to confer resistance to antiviral drugs in a phenotypic assay during NA therapy. These mutations are usually detected in patients with virologic breakthrough but they can also be present at low levels in patients whose virus levels plateau [40] .
Mechanism of Antiviral Resistance
HBV has a partially double-stranded 3.2-kb genome. Although HBV is a DNA virus, replication of viral DNA occurs via an RNA intermediate [41] . HBV has a high rate of replication, with 10 11 virions produced per day [42] . However, reverse transcriptase in the polymerase of HBV lacks a proofreading function; therefore, there is a high mutational rate of approximately 1.4-3.2 ! 10 -5 nucleotide substitutions per site per year. This rate is approximately 10-fold higher than that for other DNA viruses [43] . This enormous daily production, coupled with the high mutational rate, equals at least 10 10 point mutations produced per day in individuals who have a high level of replication [43] . Thus, it is possible that all nucleotide changes in the whole HBV genome can be produced each day. However, the organization of the open reading frame in a frame-shifted overlapping arrangement within the HBV genome does place some restriction on the final number of viable mutations that are actually generated.
The stability of the predominant HBV within the virus pool is maintained by particular selection pressures from the host's immune system and the viability and replication competence of the virus [43] . Under selection pressure generated by the presence of an antiviral agent, viruses with a mutation that confers a replication advantage are selected and eventually become the predominant viral species [40] .
Several factors are associated with the development of antiviral resistance, but the key ones -based on our current understanding -are potency, viral fitness, the genetic barrier of the antiviral agent, and patient compliance [1, 40] .
The probability of a mutation being selected during therapy depends on the potency of antiviral agents; the probability can be depicted graphically as a bell shape [44] . Hence, a drug with low antiviral activity does not exert substantial selection pressure on the virus, and the chance of drug resistance is not high. Drugs with modest antiviral activity, such as lamivudine, result in the highest probability of selecting drug resistance. Conversely, this likelihood becomes nil when virus replication is completely inhibited by antiviral agents because mutagenesis is replication dependent [43, 44] .
Replication fitness refers to the ability of the virus to replicate in a defined environment. Usually, mutant viruses show less replication fitness. However, over time, compensatory mutations such as rt80, rt180 and rt173 develop after the initial primary rtM204V/I mutation, which restores functional defects in the viral polymerase caused by the primary mutations [33] [34] [35] 45] . Even though the replication fitness of the rt204V mutant is only 10% of that of the wild type, the triple mutant, which harbors rt204, rt180 and rt173, enables the mutant virus to replicate at near wild-type levels [33, 34, 45] . Eventually, accumulation of these mutants can lead to virologic breakthrough, biochemical breakthrough and even hepatitis flare [26] .
The genetic barrier, defined as the number of amino acid substitutions needed for the development of primary antiviral drug resistance, affects antiviral resistance. Antiviral agents with a high genetic barrier (e.g. entecavir) showed low resistance rates in NAs-naïve patients [46, 47] . In contrast, antiviral agents with a low genetic barrier (e.g. lamivudine or telbivudine) showed high resistance rates [1] . Pre-existing mutations can lower the genetic barrier to resistance and increase the antiviral resistance, as is the case of the presence of the rtM204V/I mutation and the subsequent development of entecavir resistance [46, 47] .
Prevention of Antiviral Resistance
One of the most important things is to prevent antiviral resistance to avoid unnecessary treatment. Many patients with CHB will probably not benefit from current antiviral therapy, especially patients in the immune tolerant phase, usually manifested as normal ALT high viral load in young individuals [48] . The histological activity and grade of the liver showed minimal change [49] , and the virus replication is very high in this phase. If patients in the immune tolerant phase are treated with NAs, they will have a high chance of drug resistance. Therefore, the AASLD, EASL, APASL and NIH guidelines recommend that therapy should be considered only for individuals with elevated serum ALT or more active or advanced liver disease [1, 8, 10, 50, 51] .
Development of drug-resistant mutants is absolutely dependent on replication, so antiviral therapy, once initi-ated, should aim to suppress viral replication as quickly and completely as possible. Therefore, most guidelines recommend the most potent available agents, such as entecavir or tenofovir, as the first-line therapy, or peginterferon because of absence of drug-related resistance [1, 10, 50, 51] .
During NA therapy, the viral decay profiles usually present 2 distinct phases. Initially, there is a fast decay, corresponding to the clearance of free virus from circulation. It is followed by a slower second phase of decay, corresponding to the loss of infected cells [52] . Therefore, the degree of reduction of serum HBV DNA in this early phase reflects the potency of NAs in individuals regardless of antiviral agents.
In a study of 159 Chinese HBeAg-positive patients treated with lamivudine and followed up for a median of 29.6 months, resistance had developed in 8.3% of patients with undetectable serum HBV ( ! 200 copies/ml) by week 24. In contrast, it had developed in 59.9% in patients with detectable HBV DNA by week 24 [53] . Similarly, in a phase III trial of 1,367 patients treated with telbivudine or lamivudine, the degree of viral suppression at week 24 was associated with clinical and virological efficacy. Patients who achieved undetectable HBV DNA levels ( ! 300 copies/ml) at week 24 had a lower rate of resistance at 1 year than those who had HBV DNA levels of 6 4 log 10 copies/ml (2 vs. 15%) [19] . However, in adefovir-treated patients, changes in HBV DNA at week 48 were predictors for the development of resistance [31] . In patients with HBV DNA levels less than 3 log 10 copies/ml at week 48, 6% developed resistance over 192 weeks. However, in those with HBV DNA 3 log 10 copies/ml or more at week 48, 49% developed resistance over 192 weeks [31] . With entecavir, the week 24 on-treatment HBV DNA level during entecavir therapy in patients with lamivudine resistance was predictive of resistance at 2 years [54] . Thus, antiviral therapy should be modified at week 24, depending on serum HBV DNA levels.
On the basis of current available data, some experts have proposed a roadmap concept [55] . For patients with complete virological response ( ! 60 IU/ml or 300 copies/ ml at week 24), continued therapy with the same drug is recommended. In patients with partial response, defined as residual HBV DNA levels less than 2,000 IU/ml ( ! 4 log 10 copies/ml) at week 24, who are treated with a drug with a low genetic barrier to resistance, adding an appropriate non-cross-resistant second drug is recommended to prevent the emergence of resistance and viral breakthrough. However, in patients who are treated with a drug with a high genetic barrier, they recommend continuing the same drug over 48 weeks with regular monitoring of HBV DNA. In patients taking a drug with a delayed antiviral effect (e.g. adefovir), if the response remains partial or becomes inadequate at week 48, a change in therapy should be undertaken unless HBV DNA has been decreasing steadily and is nearly undetectable.
Recently, there have been efforts to prevent resistance in NA-experienced patients. Seventy-two patients, who received lamivudine therapy for over 6 months, were still positive for HBV DNA ( 6 300 copies/ml) and had no lamivudine-related mutation, were randomized into switching to entecavir 1 mg or maintaining lamivudine therapy. In a preliminary report of 34 patients who completed 48 weeks of therapy, 82% patients showed undetectable HBV DNA ( ! 300 copies/ml) in the entecavirswitched group; in contrast, only 12% patients in the lamivudine-maintained group achieved undetectable HBV DNA at week 48. In the lamivudine-maintained group, genotypic resistance occurred in 64.7% at week 48 [56] . However, no genetic resistance was observed in the entecavir-switched group. The final results of 96 weeks of therapy are awaited. Therefore, in a suboptimal response group, clinical efficacy of switching to more potent, especially non-cross-resistant, antiviral agents should be validated soon.
Management of Antiviral Resistance
During NA therapy, the first manifestation of antiviral resistance is the detection of resistant mutations (genotypic resistance). Resistant mutations may be detected at the same time or prior to virologic breakthrough. With time, serum HBV DNA levels continue to increase (viral rebound) and biochemical breakthrough develops [1] . During these serial changes, physicians should decide at which time point to change antiviral therapy.
Management of antiviral resistance has been well established by several important concepts that have emerged in recent years. In a study [57] to assess whether the timing of rescue therapy influenced virological outcome in lamivudine-resistant HBeAg-negative CHB patients (n = 74), combination therapy of lamivudine and adefovir was initiated either at the time of genotypic resistance (defined as levels of HBV DNA ^ 3-6 log 10 copies/ml and persistently normal ALT levels) and phenotypic resistance (defined as levels of HBV DNA 1 6 log 10 copies/ml and biochemical breakthrough). The 2-year rates of virological response (HBV DNA ! 2,000 copies/ ml) were 100% in the former patients and 78% in the lat-ter ones. In HBeAg-positive CHB patients (n = 207) with lamivudine resistance [58] , virological response was inversely correlated with HBV DNA levels before the initiation of rescue therapy with adefovir ( 8 lamivudine). In patients with low viremia (HBV DNA ! 5 log 10 copies/ ml), early virological response (HBV DNA ! 50 copies/ml at 6 months) occurred in 94%; in contrast, it occurred only in 4.1% of patients with high virus levels ( 1 8 log 10 copies/ml). Therefore, to optimize antiviral treatment in NA-resistant patients, rescue therapy should be initiated at the time of virologic breakthrough, which is the first clinical parameter for resistance.
The second emerging concept is a combination or switching strategy in NA-resistant patients. Two randomized controlled trials have addressed this issue [59, 60] . In the first randomized controlled study with lamivudine-resistant patients (56 HBeAg positive and 2 HBeAg negative) [59] , combination therapy with lamivudine + adefovir did not show any differences in the level of suppression of HBV DNA at 12 months compared with adefovir monotherapy. No adefovir resistance was observed at 12 months. Therefore, for several years, adefovir monotherapy had been widely used in lamivudine-resistant patients during clinical practice. However, in a study involving 95 HBeAg-positive lamivudine-resistant patients treated with adefovir for 48 weeks, the emergence of adefovir resistance was more common in lamivudine-resistant patients (18%) than in those who were treatment naïve (0%) [61] . Chen et al. [62] also showed a high incidence of adefovir resistance at month 24 (38.3%) in lamivudineresistant patients. Several recent studies have suggested that combining lamivudine with adefovir, compared with sequential monotherapy, is associated with an improvement in virological response and a lower rate of resistance in patients with lamivudine resistance [60, 63] . In a retrospective analysis of 588 lamivudine-resistant patients, 285 patients had had adefovir added in combination with lamivudine and 303 had been switched to adefovir [63] . The rates of virological response were similar in both the combined and switched groups after 3 years of therapy (78 vs. 71%, respectively). However, the rate of virologic breakthrough (6 vs. 30%) and genotypic resistance to adefovir (0 vs.16%) were significantly higher in the switched group compared to the combination group. In a subsequent small randomized controlled trial in HBeAg-negative lamivudine-resistant patients, who were treated by being switched to adefovir monotherapy or combination of adefovir with lamivudine, the virological and biochemical response rates were similar with both strategies, but adefovir resistance occurred in 21% of patients who were switched to adefovir monotherapy within 15-18 months of treatment compared to 0% in patients receiving add-on combination therapy [60] . In addition, long-term response to add-on therapy showed excellent virological outcomes and safety. The cumulative rate of virological response, genotypic resistance and virologic breakthrough, were 82, 4, and 0% at 4 years, respectively [64] . These findings suggest that add-on combination strategy in lamivudine-resistant patients is very effective in suppressing viral replication and emergence of resistance.
We are now facing the emergence of adefovir-or entecavir-resistant virus. However, there have been no well designed studies to address the issue of add-on combination or switching strategy. Nonetheless, the lessons learned from the lamivudine resistance support the use of combination therapy in patients with other drug-resistant HBV. In a retrospective study by Yang et al. [65] , out of 40 CHB patients with sequential resistance to lamivudine-adefovir, 13 patients received combination therapy of adefovir + lamivudine and 27 were switched to entecavir (1 mg) monotherapy. In patients who were switched to entecavir, the virologic breakthrough rate was 55% at 18 months. In contrast, in the combination group, the virologic breakthrough rate was 0%. This study also supports the use of combination therapy in NA-resistant patients.
Generally, nucleoside analogs (lamivudine, telbivudine, emtricitabine, entecavir) are still sensitive to resis- Tenofovir disoproxil fumarate, a nucleotide analog that is structurally closely related to adefovir [66] , has recently been approved for the treatment of CHB. Even though it was initially developed and approved for HIV, it has potent antiviral activity against wild-type or lamivudine-resistant HBV strains both in vitro and in clinical trials [22, [67] [68] [69] . In a comparative study of 53 patients with lamivudine resistance, 35 received tenofovir therapy and the remaining 18 received adefovir monotherapy. Virological response ( ! 300 copies/ml) at week 48 was 100% in tenofovir-treated patients and 44% with adefovir therapy. No genotypic resistance was observed during the follow-up of 130 weeks [68] . Therefore, we can speculate that tenofovir-based combination therapy in nucleoside analog-resistant patients can achieve better virological outcome than adefovir-based combination therapy, even though the safety of this combination is unknown. Recent guidelines prefer to recommend tenofovir-based combination therapy to adefovir-based combination therapy in nucleoside analog-resistant patients ( table 4 ) .
Conclusion
Even though NAs are very effective in suppressing HBV replication, long-term therapy with NAs is associated with the development of antiviral drug resistance. Therefore, to prevent this resistance, development of antiviral agents that act with a different mechanism and at a different site, which is the paradigm of combination therapy for HIV management, is needed. However, such antiviral agents are unlikely to become available in the near future. Therefore, an understanding of the molecular basis of NAs resistance and optimal use of NAs is important for the time being. To minimize the emergence of drug resistance using current available antiviral agents, physicians should avoid unnecessary therapy. Once anti- Not mentioned. Not mentioned. TDF resistance has not been described. It is recommended to perform genotyping and phenotyping to determine the cross-resistance profile. ETV, LdT, LMV or emtricitabine could be added.
Pre-existing LMV-resistant mutation predisposes to entecavir resistance. Truvada is a combination pill with emtricitabine 200 mg and TDF 300 mg. a TDF might be preferred over ADV as the add-on agent. AASLD = American Association for the study of the liver; EASL = European Association for the study of the liver. viral treatment is initiated, the aim should be to suppress viral replication as quickly and completely as possible. Continuous surveillance for drug resistance should be conducted. However, once antiviral resistance develops, prompt combination therapy should be initiated.
